AHNAK2 and prostate carcinoma: A higher expression of additional EMT markers (AHNAK2, LOXL2, S100A6, TGFB, TGFBR2, UCHL1, VIM, ANXA2, ANXA2P2, ANXA3, CD55, CD109) in ARLow/mCRPC/NEPC (PC3, PC3M and DU145) compared with ARHigh/mCSPC (22RV1, LnCaP) prostate cancer cell lines was also noted (Fig. 1BIII and IV).